GO:1900246 positive regulation of RIG-I signaling pathway: Antiviral Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900246 describes any process that activates or increases the frequency, rate or extent of the RIG-I signaling pathway, the cytosolic RNA-sensing cascade that triggers type I interferon and antiviral immunity.
• RIG-I (DDX58) detects short double-stranded RNA and 5'-triphosphate RNA, then signals through MAVS to activate IRF3/IRF7 and NF-kB.
• Positive regulation is achieved by RNA-binding cofactors such as ZCCHC3, by K63-linked polyubiquitination of MAVS, and by transcriptional upregulation of DDX58.
• Host proteins including IFI16, IFITM1/2 and PNMA4 enhance RIG-I signaling and restrict viruses such as influenza A virus and senecavirus A.
• Negative regulators keep RIG-I signaling in check, so loss of positive regulators can cause viral susceptibility while excessive activation can drive interferonopathies.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the main tools for dissecting which genes causally regulate this pathway.
Description
GO:1900246, positive regulation of RIG-I signaling pathway, is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of the RIG-I signaling pathway. The pathway itself begins when the cytosolic sensor RIG-I (gene symbol DDX58) binds viral RNA and initiates a signaling cascade that culminates in the production of type I interferons and pro-inflammatory cytokines. Because this cascade is a first line of defense against RNA viruses, understanding how it is positively regulated is central to antiviral immunology and to the rational design of immunomodulatory therapeutics. Positive regulation of RIG-I signaling is not a single reaction but a collection of molecular events, including RNA-induced condensation of cofactors, ubiquitin-dependent activation of the adaptor MAVS, and transcriptional induction of DDX58 itself. These events are executed by a growing list of host proteins such as ZCCHC3, IFI16, IFITM1, IFITM2 and PNMA4, each of which has been shown experimentally to enhance RIG-I-dependent antiviral responses. For researchers, GO:1900246 provides a precise annotation target when studying host factors that amplify antiviral immunity. Assigning a gene product to this term requires experimental evidence that the gene increases RIG-I signaling, distinguishing it from negative regulators that suppress the same pathway. This article summarizes the definition, mechanism, key genes, disease links and research methods relevant to GO:1900246, based on published literature and the QuickGO definition.
positive regulation of RIG-I signaling pathway At A Glance
| GO ID | GO:1900246 |
|---|---|
| GO term | positive regulation of RIG-I signaling pathway |
| Ontology | biological_process |
| Synonym | activation of DDX58 signaling pathway; activation of retinoic acid inducible gene I signaling pathway; activation of RIG-I signaling pathway; positive regulation of DDX58 signaling pathway; positive regulation of retinoic acid inducible gene I signaling pathway; positive regulation of RIG-I signalling pathway; up regulation of DDX58 signaling pathway; up-regulation of DDX58 signaling pathway; upregulation of DDX58 signaling pathway; up regulation of retinoic acid inducible gene I signaling pathway; up-regulation of retinoic acid inducible gene I signaling pathway; upregulation of retinoic acid inducible gene I signaling pathway; up regulation of RIG-I signaling pathway; up-regulation of RIG-I signaling pathway; upregulation of RIG-I signaling pathway |
| Major function | Enhances cytosolic RNA sensing and downstream type I interferon and pro-inflammatory cytokine production |
| Core sensor | RIG-I (DDX58), a cytosolic DExD/H-box RNA helicase |
| Key adaptor | MAVS, which transmits RIG-I signals to TBK1/IKK and IRF3/NF-kB |
| Representative positive regulators | ZCCHC3, IFI16, IFITM1, IFITM2, PNMA4, USP18 |
| Opposing process | Negative regulation of RIG-I-like receptor signaling pathway |
What Is GO:1900246?
In simple terms, GO:1900246 covers any biological process that boosts the RIG-I signaling pathway. The QuickGO definition states: Any process that activates or increases the frequency, rate or extent of RIG-I signaling pathway. This includes direct activation of RIG-I (DDX58) or its downstream adaptor MAVS, stabilization of signaling complexes, and increased expression of pathway components, as long as the net effect is enhanced RIG-I-dependent signaling.
Why Is positive regulation of RIG-I signaling pathway Important in Cell Biology?
Positive regulation of RIG-I signaling is important because it determines the strength and speed of the innate antiviral response. RIG-I-like receptors are essential for detecting RNA viruses, and their positive regulators can tip the balance toward viral clearance rather than viral replication. Experimental evidence shows that enhancing this pathway restricts viruses such as influenza A virus and senecavirus A, while failure to activate it can permit viral spread. At the same time, because the same pathway can drive interferonopathies when overactivated, positive regulators are attractive but delicate therapeutic targets. GO:1900246 therefore provides a framework for annotating host factors that amplify antiviral immunity and for interpreting genetic or pharmacological perturbations of this cascade.
• Defines the molecular events that amplify cytosolic RNA sensing by RIG-I (DDX58).
• Controls the magnitude of type I interferon and pro-inflammatory cytokine induction.
• Explains how host cofactors such as ZCCHC3 promote broad innate immune responses.
• Links K63-linked polyubiquitination of MAVS to enhanced antiviral immunity.
• Provides a mechanism for transcriptional reinforcement of RIG-I signaling via IFI16.
• Highlights positive feedback loops, such as IFITM1/IFITM2 with RIG-I signaling, that restrict viral replication.
• Identifies PNMA4 as a positive regulator that enhances anti-RNA virus immunity.
• Distinguishes positive regulators from negative regulators that prevent immunopathology.
• Supports antiviral drug and adjuvant discovery targeting RIG-I pathway amplification.
• Offers CRISPR-tractable gene sets for functional genomics of antiviral immunity.
What Happens During positive regulation of RIG-I signaling pathway?
RNA sensing and RIG-I activation
In simple terms: RIG-I must first grab viral RNA before any positive regulation can occur.
RIG-I (DDX58) is a cytosolic helicase that recognizes short double-stranded RNA and RNA bearing a 5'-triphosphate end, which are hallmarks of viral infection. Positive regulation of the pathway often begins at this step, because cofactors that promote RIG-I RNA binding or stabilize the RNA-bound conformation increase downstream signaling. For example, nucleic-acid-induced condensation of ZCCHC3 promotes broad innate immune responses by facilitating RIG-I signaling.
Signal transmission via MAVS
In simple terms: After RIG-I is activated, it passes the alarm to MAVS, which relays the signal onward.
Activated RIG-I interacts with the mitochondrial antiviral signaling protein MAVS, which serves as the central adaptor for RIG-I-like receptor signaling. Positive regulation at this stage includes K63-linked polyubiquitination of MAVS, a modification that promotes its signaling activity; USP18 positively regulates innate antiviral immunity by promoting this ubiquitination event. Ubiquitination is a recurring theme in the positive regulation of antiviral RIG-I signaling.
Transcription of RIG-I and pathway components
In simple terms: Cells can make more RIG-I protein to strengthen the pathway.
Positive regulation can also occur at the transcriptional level. IFI16 directly senses viral RNA and enhances RIG-I transcription and activation to restrict influenza virus infection, illustrating how a DNA-binding sensor can amplify the RIG-I pathway. This transcriptional reinforcement increases the available pool of RIG-I, making the cell more responsive to subsequent RNA challenge.
Positive feedback and amplification loops
In simple terms: Some antiviral proteins both depend on and boost RIG-I signaling, creating a feedback loop.
IFITM1 and IFITM2 inhibit the replication of senecavirus A by positive feedback with the RIG-I signaling pathway, demonstrating that interferon-stimulated genes can feed back to enhance RIG-I-dependent responses. Similarly, PNMA4 enhances anti-RNA virus immunity by promoting the RIG-I signaling pathway. These examples show that positive regulation of GO:1900246 can be embedded in broader antiviral networks rather than acting as a single linear step.
Balancing positive and negative regulation
In simple terms: The pathway must be turned up when needed and turned down to avoid damage.
Positive regulation of RIG-I signaling is counterbalanced by negative regulators of the RIG-I-like receptor signaling pathway, which prevent excessive inflammation. The existence of both positive and negative regulators means that the net output of GO:1900246 depends on the relative activity of opposing factors. This balance is critical because too little signaling permits viral replication, whereas too much can contribute to inflammatory pathology.
Key Genes Involved in GO:1900246 positive regulation of RIG-I signaling pathway
The following genes and proteins have been experimentally implicated in the positive regulation of RIG-I signaling (GO:1900246) or in the core pathway it regulates.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DDX58 (RIG-I) | Cytosolic RNA sensor that initiates the pathway | Core sensor; knockout abolishes RIG-I-dependent antiviral signaling |
| MAVS | Mitochondrial adaptor transmitting RIG-I signals | K63-linked polyubiquitination of MAVS enhances signaling |
| ZCCHC3 | RNA-binding cofactor that condenses upon nucleic acid sensing | Promotes broad innate immune responses and RIG-I signaling |
| IFI16 | Nuclear sensor that enhances RIG-I transcription and activation | Restricts influenza virus infection via RIG-I upregulation |
| IFITM1 | Interferon-induced antiviral effector | Positive feedback with RIG-I signaling restricts senecavirus A |
| IFITM2 | Interferon-induced antiviral effector | Positive feedback with RIG-I signaling restricts senecavirus A |
| PNMA4 | Positive regulator of RIG-I signaling | Enhances anti-RNA virus immunity |
| USP18 | Deubiquitinase promoting K63-linked polyubiquitination of MAVS | Positively regulates innate antiviral immunity |
| TBK1 | Kinase downstream of MAVS | Phosphorylates IRF3 to induce interferons |
| IKK family | Kinases activating NF-kB | Drive pro-inflammatory cytokine expression downstream of RIG-I |
| IRF3 | Transcription factor for type I interferon genes | Readout of RIG-I pathway activation |
| IRF7 | Transcription factor amplifying interferon production | Contributes to positive feedback of antiviral signaling |
| TRIM25 | E3 ubiquitin ligase acting on RIG-I | Ubiquitination is a key positive regulatory mechanism |
| RNF135 | E3 ubiquitin ligase implicated in RIG-I activation | Ubiquitin-dependent positive regulation of antiviral signaling |
| NF-kB subunits | Transcription factors for inflammatory cytokines | Downstream effectors of RIG-I signaling |
| ISG15 | Interferon-stimulated ubiquitin-like modifier | Part of antiviral positive feedback networks |
| ATG5-ATG12 | Autophagy-related conjugate | Modulates RIG-I signaling in antiviral immunity |
How Is positive regulation of RIG-I signaling pathway Regulated?
Positive regulation of RIG-I signaling is itself tightly regulated at multiple levels. Ubiquitination and deubiquitination reactions control the stability and activity of RIG-I and MAVS, with K63-linked polyubiquitination of MAVS serving as a positive regulatory modification. Negative regulators of the RIG-I-like receptor signaling pathway provide an opposing layer that prevents excessive interferon production. Transcriptional control adds another layer, as seen when IFI16 enhances RIG-I transcription during influenza virus infection. Finally, positive feedback loops involving interferon-stimulated genes such as IFITM1 and IFITM2 can sustain pathway activity after initial activation.
positive regulation of RIG-I signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DDX58 (RIG-I) | RNA virus susceptibility and interferonopathy | Knockout and point-mutation cell lines challenged with RNA virus |
| MAVS | Antiviral immunity and inflammatory signaling | Knock-in of ubiquitination-site mutants to test K63-linked modification |
| IFI16 | Influenza virus infection restriction | Overexpression and knockout models to measure RIG-I transcription |
| IFITM1 / IFITM2 | Senecavirus A replication restriction | Knockout and overexpression with RIG-I pathway readouts |
| PNMA4 | Anti-RNA virus immunity | Knockout and overexpression in antiviral assays |
Viral infection and antiviral restriction
Positive regulation of RIG-I signaling is directly relevant to viral infection because the pathway restricts replication of RNA viruses. IFI16 enhances RIG-I transcription and activation to restrict influenza virus infection, and IFITM1/IFITM2 inhibit senecavirus A replication through positive feedback with RIG-I signaling. PNMA4 similarly enhances anti-RNA virus immunity by promoting RIG-I signaling. These findings suggest that loss of positive regulators could increase susceptibility to RNA viruses.
Innate immune homeostasis and interferonopathies
Because RIG-I signaling must be balanced, dysregulation of positive regulation can contribute to inflammatory pathology. Negative regulators of the RIG-I-like receptor signaling pathway exist to prevent excessive immune activation. When positive regulation dominates, excessive type I interferon and pro-inflammatory cytokines may drive autoinflammatory or interferonopathic states. Conversely, insufficient positive regulation may impair antiviral defense.
Host-pathogen interactions and immune evasion
Viruses often target positive regulators of RIG-I signaling to evade immunity. The central role of ubiquitination in antiviral RIG-I signaling makes it a common target for viral antagonism. Understanding which host factors positively regulate GO:1900246 can therefore reveal points of vulnerability exploited by pathogens.
From positive regulation of RIG-I signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for RIG-I signaling? | CRISPR knockout cell line with RNA virus challenge |
| Does a specific ubiquitination site on MAVS mediate positive regulation? | Point-mutation knock-in of MAVS ubiquitination sites |
| Does a cofactor enhance RIG-I signaling when tagged? | Tagged knock-in for imaging and interaction studies |
| Does overexpression of a positive regulator restrict viral replication? | Overexpression cell model with viral titer readout |
| Which genes amplify RIG-I-dependent interferon output? | CRISPR library screening with interferon reporter |
| Does a transcription factor increase DDX58 expression? | Knockout and overexpression with RIG-I transcription assays |
How to Study the positive regulation of RIG-I signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes in antiviral genes | Detect RIG-I pathway amplification and feedback |
| Proteomics / ubiquitin profiling | Post-translational modifications of RIG-I and MAVS | Test K63-linked polyubiquitination of MAVS |
| Co-immunoprecipitation | Protein-protein interactions in signaling complexes | Map cofactor binding to RIG-I or MAVS |
| Fluorescence microscopy | Condensation and localization of signaling proteins | Visualize ZCCHC3 condensation upon RNA sensing |
| Interferon reporter assay | Type I interferon promoter activity | Quantify positive regulation of RIG-I signaling |
| Viral infection assay | Viral replication and restriction | Test influenza virus or senecavirus A restriction |
| CRISPR knockout screening | Gene requirement for pathway activity | Identify positive regulators of RIG-I signaling |
| Western blot | Protein levels and phosphorylation status | Measure IRF3 phosphorylation and RIG-I abundance |
RNA sequencing and transcriptomics
RNA-seq can quantify expression of DDX58, MAVS and interferon-stimulated genes after perturbation of candidate positive regulators. This approach is useful for detecting transcriptional reinforcement of RIG-I signaling, as shown for IFI16-mediated enhancement of RIG-I transcription. Differential expression of antiviral gene programs can also reveal positive feedback loops involving IFITM1 and IFITM2.
Proteomics and ubiquitination analysis
Mass spectrometry-based proteomics can identify ubiquitination events on RIG-I and MAVS that underlie positive regulation. Because K63-linked polyubiquitination of MAVS enhances antiviral immunity, ubiquitin remnant profiling is a direct way to test whether a candidate regulator promotes this modification. Interaction proteomics can also map cofactor complexes such as ZCCHC3 condensates.
Imaging and condensation assays
Fluorescence microscopy can visualize nucleic-acid-induced condensation of cofactors such as ZCCHC3, which promotes innate immune signaling. Live-cell imaging of tagged RIG-I or MAVS can reveal how positive regulators alter signaling complex assembly and localization.
Antiviral functional assays
Viral infection assays with influenza virus, senecavirus A or other RNA viruses can measure the functional consequence of manipulating positive regulators. IFI16, IFITM1/2 and PNMA4 have all been tested in such assays, linking GO:1900246 to measurable antiviral restriction.
How CRISPR Can Be Used to Study GO:1900246 positive regulation of RIG-I signaling pathway
Knockout
CRISPR knockout of candidate genes is used to test whether they are required for positive regulation of RIG-I signaling. For example, knocking out DDX58 abolishes RIG-I-dependent sensing, while knocking out cofactors such as ZCCHC3 or IFI16 can reduce antiviral responses. Knockout models are also valuable for distinguishing positive regulators from negative regulators of the pathway.
Point Mutation
Point-mutation models allow precise testing of post-translational modification sites. Because K63-linked polyubiquitination of MAVS promotes antiviral immunity, mutating specific lysine residues can determine whether ubiquitination is required for positive regulation. Similarly, point mutations in RIG-I domains can separate RNA binding from signaling activation.
Knock-in
Knock-in of tags or reporters enables visualization and biochemical isolation of pathway components. Tagged knock-in of cofactors such as ZCCHC3 can support imaging of nucleic-acid-induced condensation. Knock-in of reporter cassettes downstream of interferon or NF-kB response elements provides a quantitative readout of GO:1900246 activity.
Overexpression
Overexpression models test sufficiency: if a gene positively regulates RIG-I signaling, overexpressing it should enhance interferon induction or restrict viral replication. IFITM1, IFITM2 and PNMA4 have been studied in this way, showing positive effects on RIG-I-dependent antiviral responses. Overexpression of IFI16 likewise enhances RIG-I transcription and activation.
How EDITGENE Supports positive regulation of RIG-I signaling pathway Research
Researchers studying positive regulation of RIG-I signaling pathway-related genes often need to determine whether a candidate gene is causally involved in enhancing antiviral immunity or is merely correlated with pathway activation. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the causal evidence required to assign a gene to GO:1900246 with confidence.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of RIG-I signaling pathway research.
Frequently Asked Questions About positive regulation of RIG-I signaling pathway
What is GO:1900246?
GO:1900246 is the Gene Ontology term for positive regulation of RIG-I signaling pathway, defined as any process that activates or increases the frequency, rate or extent of RIG-I signaling pathway.
What is the RIG-I signaling pathway?
The RIG-I signaling pathway is a cytosolic RNA-sensing cascade in which RIG-I (DDX58) detects viral RNA and signals through MAVS to induce type I interferons and pro-inflammatory cytokines.
What genes are involved in positive regulation of RIG-I signaling pathway?
Genes include DDX58 (RIG-I), MAVS, ZCCHC3, IFI16, IFITM1, IFITM2, PNMA4 and USP18, all of which have been experimentally linked to enhanced RIG-I-dependent antiviral signaling.
How is RIG-I signaling positively regulated?
Positive regulation occurs through RNA-induced cofactor condensation, K63-linked polyubiquitination of MAVS, transcriptional upregulation of DDX58, and positive feedback loops involving interferon-stimulated genes.
What is the role of MAVS in RIG-I signaling?
MAVS is the mitochondrial adaptor that transmits signals from activated RIG-I to downstream kinases and transcription factors, and its K63-linked polyubiquitination enhances antiviral immunity.
Which viruses are restricted by positive regulation of RIG-I signaling?
Influenza virus and senecavirus A are examples of RNA viruses whose replication is restricted when RIG-I signaling is positively regulated by factors such as IFI16, IFITM1 and IFITM2.
How can I study positive regulation of RIG-I signaling with CRISPR?
CRISPR knockout, point-mutation, knock-in and overexpression models can test requirement and sufficiency of candidate genes, while CRISPR library screening can identify new positive regulators.
What are negative regulators of RIG-I signaling?
Negative regulators are host factors that suppress the RIG-I-like receptor signaling pathway to prevent excessive inflammation, and they oppose the activity described by GO:1900246.
Why is balance important in RIG-I signaling?
Too little RIG-I signaling permits viral replication, while too much can cause inflammatory or interferonopathic pathology, so positive and negative regulators must be balanced.
What experimental readouts measure positive regulation of RIG-I signaling?
Common readouts include interferon reporter assays, IRF3 phosphorylation by western blot, RNA-seq of interferon-stimulated genes, and viral infection assays.
Conclusion
GO:1900246, positive regulation of RIG-I signaling pathway, captures the diverse mechanisms that amplify cytosolic RNA sensing and antiviral immunity. From RNA-induced condensation of ZCCHC3 to K63-linked polyubiquitination of MAVS and transcriptional enhancement by IFI16, positive regulators shape the strength of type I interferon responses. Because the same pathway must be restrained to avoid inflammatory damage, positive regulators are both biologically fascinating and therapeutically delicate. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with RNA-seq, proteomics and antiviral assays, provide the experimental toolkit needed to assign genes to this term with confidence.
References
- 1. Shi M et al.. 2025. Nucleic-acid-induced ZCCHC3 condensation promotes broad innate immune responses.. Mol Cell 85(5):962-975.e7 PMID: 39983719
- 2. Quicke KM et al.. 2017. Negative regulators of the RIG-I-like receptor signaling pathway.. Eur J Immunol 47(4):615-628 PMID: 28295214
- 3. Hou J et al.. 2021. USP18 positively regulates innate antiviral immunity by promoting K63-linked polyubiquitination of MAVS.. Nat Commun 12(1):2970 PMID: 34016972
- 4. Jiang Z et al.. 2021. IFI16 directly senses viral RNA and enhances RIG-I transcription and activation to restrict influenza virus infection.. Nat Microbiol 6(7):932-945 PMID: 33986530
- 5. Li H et al.. 2024. IFITM1 and IFITM2 inhibit the replication of senecavirus A by positive feedback with RIG-I signaling pathway.. Vet Microbiol 292:110050 PMID: 38484578
- 6. Ramos HJ et al.. 2011. RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity.. Curr Opin Virol 1(3):167-76 PMID: 21949557
- 7. Song H et al.. 2025. PNMA4 enhances anti-RNA virus immunity by promoting RIG-I signaling pathway.. Int Immunopharmacol 165:115446 PMID: 40929959
- 8. Maelfait J et al.. 2012. Emerging role of ubiquitination in antiviral RIG-I signaling.. Microbiol Mol Biol Rev 76(1):33-45 PMID: 22390971
